Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Journal of Inflammation (London, England)|November 7, 2015
E-selectin and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in cerebrovascular diseasesSébastien Richard, Linnéa Lagerstedt, Pierre R Burkhard, et al.
Journal of Neurology|May 19, 2017
Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance dataStéphanie Foulon, Géric Maura, Marie Dalichampt, et al.
Neuroepidemiology|August 10, 2017
Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort StudyFrancis Guillemin, Cédric Baumann, Jonathan Epstein, et al.
Journal of Neurology|April 1, 2021
Long-term analysis of patients with benign multiple sclerosis: new insights about the disability courseGuillaume Mathey, Guillaume Pisché, Marc Soudant, et al.
Journal of Neurology|February 29, 2024
Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life studyLouisa Scherer, Marc Soudant, Sophie Pittion-Vouyovitch, et al.
BMC Neurology|December 1, 2014
Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosisPhilippe Manceau, Clotilde Latarche, Sophie Pittion, et al.
Journal of Crohn'S & Colitis|November 29, 2025
Inflammatory Bowel Disease therapies and Demyelinating Diseases: A Practical Guide to Therapeutic Benefit and RiskSailish Honap, Marc Debouverie, Massimo Filippi, et al.
Medicine|June 17, 2016
Simulation training for emergency teams to manage acute ischemic stroke by telemedicineSébastien Richard, Gioia Mione, Claude Varoqui, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 6, 2021
Cumulative effects of therapies on disability in relapsing multiple sclerosisFabien Rollot, Romain Casey, Emmanuelle Leray, et al.
Pageof 8